Advances in payload-linker technology have made ADCs a major therapeutic modality, prompting drug developers to strive for greater selectivity and safety in the next wave of ADCs.
From evolving strategic partnerships to emerging technologies and supply chain resiliency — learn how CDMOs are adapting to the new OSD manufacturing playbook.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Regulatory momentum, device innovation, and advances in formulation science are
repositioning the nasal route as a strategic option for systemic and CNS therapies—provided sponsors address translational and development challenges early.
SGS supports pharmaceutical and biopharmaceutical clients from development through commercialization with a comprehensive portfolio of expert-led GMP quality control and analytical testing services for raw materials, APIs, packaging components, and finished drug products. Our teams apply disciplined science and regulatory expertise across small and large molecule programs to support product characterization, comparability, stability, and final GMP product release.
CMC Pharma expedites drug product development with flexible lab services tailored to every stage of development. FDA-registered and inspected labs are equipped to conduct both routine & customized drug product development studies to ensure the purity and potency of the finished drug product through product approval and commercialization.
